Hutchison China Meditech Limited Chi-Med to Announce Half-Year Financial Results (9064S)
June 29 2018 - 2:01AM
UK Regulatory
TIDMHCM
RNS Number : 9064S
Hutchison China Meditech Limited
29 June 2018
Chi-Med to Announce 2018 Half-Year Financial Results
London: Friday, June 29, 2018: Hutchison China MediTech Limited
("Chi-Med") (AIM/Nasdaq: HCM) will be announcing its interim
results for the six months ended June 30, 2018 on Friday, July 27,
2018 at 7:00 am British Summer Time (BST).
An analyst presentation will be held at 9:00 am BST (4:00 pm
Hong Kong Time) on the same day at Citigate Dewe Rogerson, 3 London
Wall Buildings, London, EC2M 5SY, UK, which will be webcast via the
company website at www.chi-med.com/investors/event-information/.
The presentation will be available to download before the analyst
presentation begins.
For North America based analysts and investors, Chi-Med will
also host a conference call with Q&A at 9:00 am Eastern
Daylight Time (2:00 pm BST).
Details of the analyst presentation and conference call dial-in
will be provided in the financial results announcement. A replay
will also be available on the website shortly after each event.
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which
researches, develops, manufactures and sells pharmaceuticals and
healthcare products. Its Innovation Platform, Hutchison MediPharma
Limited, focuses on discovering and developing innovative
therapeutics in oncology and autoimmune diseases for the global
market. Its Commercial Platform manufactures, markets, and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 1). For more information, please
visit: www.chi-med.com.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President,
Corporate Finance & Development +852 2121 8200
U.K. & International Media Enquiries
Anthony Carlisle, +44 7973 611 888 (Mobile)
Citigate Dewe Rogerson anthony.carlisle@cdrconsultancy.co.uk
U.S. Based Media Enquiries
Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Susan Duffy, Solebury Trout +1 (917) 499 8887 (Mobile)
sduffy@troutgroup.com
Investor Relations
Xuan Yang, Solebury Trout +1 (415) 971 9412 (Mobile)
xyang@troutgroup.com
David Dible, +44 7967 566 919 (Mobile)
Citigate Dewe Rogerson david.dible@citigatedewerogerson.com
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORFMGZVLRKGRZG
(END) Dow Jones Newswires
June 29, 2018 02:01 ET (06:01 GMT)
Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Apr 2023 to Apr 2024